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A new generation of innovative receptor targeted drugs rapidly enters the market.
However, since these drugs target a specific receptor, they are not of value for all
cancer patients, but only for specific tumor types or a subset within a tumor type. This
makes it increasingly important to select the patients that might benefit from the
targeted therapy and offers a potential role for receptor imaging with radiolabeled
variants of these drugs.
This thesis aimed to study receptor targeted drugs and focused on recombinant
human TNF-re lated apoptosis  inducing l igand ( rhTRAlL)  and t rastuzumab and thei r
radiolabeled counterparts, intended to target and visualize the death recePtor and the
human epidermal growth factor receptor 2 (HER2/erb82) respectively.
TRAIL is a member of a subfamily within the TNF-superfamily of cytokines, also called
the death receptor l igands or death factors, that are able to induce apoptosis upon
binding to thei r  death receptors.  Trastuzumab is  a humanized lgGl  monoclonal
antibody directed against HER2. HER2 is a receptorfor regulation of cell survival. The
HER2 receptor is overexpressed in a wide variety of human cancers, including 25-30%
of primary breast cancers. Trastuzumab, by blocking the growth signal, and rhTRAlL,
by directly init iating apoptosis, are both in different ways able to change the apoptosis
balance in tumor cells after binding to their cognate cell surface receptor.
In chapter 2 an overview is presented concerning regulation of cell death and cell
survival by death receptor l igand and HER signaling pathways. Attention is paid to
rhTRAlL and trastuzumab and to novel opportunities for receptor imaging. Data
regarding death receptor imaging and imaging of HER-receptor family have been
reviewed and c lear ly  i l lust rate that  molecular  imaging techniques can be used in
staging and restaging, evaluation and prediction of treatment response and
characterization of lesions, as they permit total body imaging in a non-invasive way.
With the development of these new generation of targeted agents, molecular imaging
may become an important part of future clinical studies and clinical practice,
support ing indiv idual ized cancer therapy.
The first part of the thesis (chapters 3-6) is dedicated to TRAIL. To learn more about
the physiological role of TRAIL we have studied soluble (s)TRAIL concentrations in
two non cancer settings namely, sepsis and systemic lupus erythematosis (SLE).
SUMMARY
Intensive research has brought us an enormous body of knowledge about sepsis and
the mechanisms behind it. The involvement of the immune and the coagulation
system has received much attention. Currently, dysregulation of the immune system
is considered to be the most important factor that determines outcome. The role of
apoptosis in the regulation of the immune response is well recognized, but its role in
the dysfunction of other organs and in the mortality due to sepsis is less clear. TNFcr is
one of the bridges between the inflammatory reaction and apoptosis. The role that
the other death l igands Fas l igand (FasL) and TRAIL play, is far less known. There are
however increasing indications that TRAIL is also involved in inflammatory processes.
These data raised the question whether sTRAIL is involved in sepsis.
A human endotoxemia model is available in which some aspects of sepsis can be
studied. In chapter 3, the effect of endotoxin administration (4 ng/kg body weight
(10,000 endotoxin U/pg)  as a 1-min in fus ion)  on the response of  sTRAlL,  and the ro le
of  p38 MAP k inase (K)  inh ib i t ion was studied in  21 human volunteers.  p38 MAPK
inhibitors are considered potential drugs in inflammatory diseases. Thirty minutes
before the endotoxin infusion, the volunteers received a single oral dose of placebo or
the selective p38 MAPK inhibitor drug, RWJ-67657. We tested the RWJ-67657 dose
levels 1400 mg (n = 4) ,700 mg (n = 6) ,350 mg (n = 5) ,  and 0 mg (n = 6) .  B lood for
sTRAIL analys is  was drawn predose,  and 1,  1 .5,2,2.5,3.5,4.5,  6.5,8,  and 24 hours af ter
endotoxin infusion. Plasma levels of sTRAIL were determined with a validated solid-
phase sandwich enzyme-linked immunosorbent assay (ELISA). At t = 0 before the
endotoxin infusion, the median sTRAIL level in the placebo group was 681 t 86.8
pg/ml  (mean t  SEM, n = 6) .  This  level  can be considered as the normal  va lue in  young
restingmales in the morning. Plasma sTRAIL increased 10-fold to6564 t 5'11 pg/mL
after 2.5 hours. This increase was blocked completely by the highest dose of RW-
67657 (1400 mg). The sTRAIL levels were already lowering ' l hour later (p=0.003,
Student's f test) and were normalized 6.5 hours after endotoxin infusion (p=0.98).
After a dose of 350 mg or 750 mg RWJ-67657, sTRAIL levels 24 hours after endotoxin
infusion were elevated. The peak levels (t = 3.5 h) were 2729.2 t 328.0 pg/ml and
3155.4 t 645.3 pg/mL respectively. However no dose response relation was found.
In conclusion, sTRAIL is responsive to endotoxemia. However, the precise role in
sepsis remains to be elucidated. lf sTRAIL turns out to participate in the pathogenesis




Increased apoptosis  may induce auto immune condi t ions.  SLE is  an auto immune
disease with a wide spectrum of clinical and immunological abnormalit ies. The
presence of autoantibodies, especially those directed to double stranded DNA' is
characteristic for the disease. SLE may affect different organ systems, including the
skin, joints, central and peripheral nervous system, kidneys, and liver' The etiology of
SLE remains unknown. There is however increasing evidence that the Presence and
accumulation of apoptotic cells play a role in autoimmunity. Apoptosis is induced by
binding of death recePtor l igands to their cognate receptors' The Fas-FasL pathway
has been studied extensively in relation to SLE. However, other death pathways are
also considered important and we hypothesized that secreted sTRAIL might be
important in the induction of apoptosis in SLE'
The aim of chapter 4 was to assess TRAIL concentrations in sera of SLE patients.
Forty SLE patients were studied (20 with active disease and 20 with inactive disease).
Serum sTRAIL levels were measured by a validated ELISA. Serum sTRAIL levels in SLE
patients were comPared with those in patients with rheumatoid arthrit is (n=20),
Wegener's granulomatosis (n=20) and healthy controls (n=20). Mean serum sTRAIL
concentration (t SEM) in SLE patients (936.0 t 108.2 pgimL) was higher than in
heal thy contro ls  (509.4 t  33.8 pg/mL,  p<0.01)and in d isease contro l  pat ients wi th
rheumatoid arthrit is (443.5 t 36.' l  pg/mL, p<0.001) or wegener's granulomatosis
(357.1 x 32.2 pglmL, p<0.001). The mean serum sTRAIL concentration was 1010.2 t
168.0 pg/mL for patients with inactive disease and 861.8 t 138.7 Pg/mL for patients
with active disease. Soluble TRAIL values were not correlated with specific
mani festat ions of the d isease,  such as leucopenia or  lymphopenia,  orwi th SLE disease
activity index.
In conclusion, this study reports that serum sTRAIL concentrations are increased in
SLE patients. This seems to be disease specific and could indicate a role for TRAIL in
SLE pathophysiology.
Of the death receptor l igands, especially TRAIL might be an interesting candidate to
facil i tate the apoptotic process in combination with chemotherapeutic drugs, as it can
induce apoptosis in transformed cell l ines, but not in normal cells, by bindingto its cell
membrane receptors. A non-commercial production of rhTRAlL was set up to allow a
cl in ica l  phase I s tudy.
SUMMARY
In chapter 5 we described an approach for the production of clinical grade rhTRAlL
meeting requirements of Good Manufacturing Practice and regulatory guidelines of
the European Agency for the Evaluation of Medicinal Products assuring quality and
safety of the product. RhTRAIL was produced by recombinant DNA techniques in
Escherichia coli BL21-S| cells. Competent BL21-sl cells were transformed with
pET15b-TRAlL114-281plasmid, that harbors the gene encoding soluble human TRAIL,
corresponding to the extracel lu lar  par t  of  the TRAIL molecule ( i .e .  amino acids 114_
281)' Soluble rhTRAlL was recovered from host BL21-Sl cell lysates by sonication and
was subsequently purif ied by sp-sepharose Fast Frow cation exchange
chromatography, nickel-nitri lotriacetic acid affinity chromatography and dialysis.
Three consecutive production batches were run. An extensive range of in-process and
characterization tests was performed to show batch-to-batch consistency with regard
to identity, purity and biorogicar activity. The recombinant protein was then
formulated in a TRIS buffer containing zinc, glycerol, Nacl, and human serum arbumin
and stored in polypropylene vials at -g0 "C.
Because of the shown anti-tumor activity in tumor xenograft moders and the rack of
systemic toxicity in mice, cynomolgus monkeys and chimpanzees, rhrRArL is now
under investigation as a therapeutic agent. The physiological role of TRA|L and the
pharmacokinetic behavior of rhrRAlL are complex and sti l l  not fully understood.
Availabil ity of radiolabeled rhTRAlL would offer the possibil i ty of molecular imaging in
humans to study biodistribution and whole body pharmacokinetics. Furthermore
imaging enables to i l lustrate whether the drug reaches the target.
In chapter 6 radioiodinated rhTRAlL was developed to study in_vitro and in_vivo
death receptor targeting and pharmacological behavior in a human tumor bearing
mice model. In order to deverop a tracer suitabre for imaging in patients, much
attention was paid to optimization and validation of the labeling process, to stabil ity
testing and to show maintenance of receptor binding properties.
RhTRAIL radioiodination was optimized using chloramine T as oxidizing agent.
Radiochemical purity and stabil ity of 12sl-rhTRAlL in TRls-buffer and human serum
were determined by size exclusion chromatography HpLC. lmmunoreactivity and
receptor binding properties were examined using different TRAIL receptor positive
tumor cel l  l ines.
CHAPTER 9
12sl-rhTRAlL biodistribution was assessed in a biodistribution study using athymic
mice bearing human SKBR3 or SW948 xenografts with different TRAIL receptor
expression levels.
12sl-rhTRAlL (labeling yield 70.3 x 1.1 %, radiochemical purity > 98%, specific activity
0.75 t 0.05 MBq/Ug) was stable in TR|S-buffer and human serum for 24 h although
free iodine and h igh molecular  weight  compounds gradual ly  developed (16 and 19 %
respectively after 72 h). The immunoreactive fraction, determined using the Colo320
tumor cell l ine, was 0.80 t 0.08 (n=4). A concentration of 9.3x10-8 M rhTRAlL was
needed to reduce t2sl-TRAIL binding with 50%. Due to competit ion with soluble DR5
(5 ptg) binding of 12sl-rhTRAlL (5 ng) to various cell l ines was considerably reduced
with 56% in SW948 and up to 74% in Colo320. t2sl-rhTRAll biodistribution is
characterized by fast renal elimination. Uptake rapidly decreased in all normal t issues.
SW948 tumor uptake however, although only 1.1% of the injected doseig, increased
over time.
In conclusion, rhTRAlL can be efficiently radioiodinated. Radioiodinated rhTRAlL binds
to the TRAIL receptors in-vitro and in-vivo and can be used in humans for death
receptor imaging.
The second part of this thesis (chapters 7 and 8) is dedicated to the anti-HER2
monoclonal antibody trastuzumab. Trastuzumab is an exciting new targeted drug with
an unique mechanism of action, that is currently approved for the treatment of
patients with HER2 overexpressing metastatic breast cancer. In addition to its use in
the metastatic breast cancer setting, impressive results of large randomized
multicenter trials, designed to evaluate the use of adjuvant rastuzumab, were recently
reported. The studies showed highly significant reductions in the risk of recurrence,
prolongation of disease free and overall survival in the adjuvant reatment of patients
with HER2 oositive breast cancer.
Unfortunately, even when strong HER2 overexpression (3+) is present, part of the
patients do not respond to trastuzumab therapy. Moreover, during trastuzumab
treatment patients can develop severe cardiac dysfunction. The mechanism of the
trastuzumab-induced cardiac toxicity is sti l l  unclear, but might be related to specific
binding to HER2 receptors expressed in the myocardium. A reliable test for the
prediction of tumor response and the risk of developing cardiac failure is therefore
urgently needed. This was the main motivation for the development of radiolabeled
trastuzumab that is described in chapter 7.
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SUMMARY
The aim of  th is  s tudy was to develop c l in ica l  gradel l l lnd ium 1111lny radio labeled
trastuzumab, to evaluate the stabil ity and immunoreactivity of the tracer and to
perform a biodistribution study in human tumor-bearing mice. Trastuzumab was
radio labeled wi th 1111n using cyc l ic  anhydr ide d iethy lenetr iamine pentaacet ic  ac id
(cDTPA) as a chelator . t t l ln-DTPA-trastuzumab ( label ing y ie ld 92.3 x 2.3%,
radiochemical purity 97.0 + 1.5%) is stable in phosphate buffered saline when stored at
4"C for more than 14 days. The immunoreactive fraction determined by cell-binding
assays,  us ing the HER2-overexpressing human ovar ian SKOV3 tumor cel l  l ine,  was
0.87 t 0.06. Eiodistribution and tumor targeting were studied in HER2 receptor-
positive and HER2-negative tumor-bearing athymic mice. The HER2-positive tumor
showed (9.77 x 1.14% iniected dose per gram) substantial uptake of the labeled
antibody already after 5 hours. The difference in uptake between HER2-positive versus
HER2-negative tumors was even more pronounced 3 days after injection (16.30 t
0.64% iniected dose per gram), and was visualized by radioimmunoscintigraphy. Liver,
spleen, and kidney showed marked tracer uptake.
In summary,  we showed that  t rastuzumab can be ef f ic ient ly  radio labeled wi th111ln
resul t ing in  h igh label ing y ie lds and h igh stabi l i ty .  t " ln-DTPA-trastuzumab select ive ly
binds to the human HER2 receptor both in-vitro and in-vivo in animals. Therefore,
1 1 1 ln-DTPA-trastuzumab a ppea red suita ble for clinical use.
Chapter  8 descr ibed the c l in ica l  s tudy that  a imed to evaluate whether l l l ln- labeled
trastuzumab scintigraphy can predict cardiotoxicity and identifo tumor lesions. In
addition, we evaluated whether plasma markers for cardiac dysfunction can be used to
predict ca rdiotoxicity.
Patients with HER2-positive metastatic breast cancer underwent gammacamera
imaging f rom 15 minutes to 7 days af ter  in ject ion of  150 MBqt" ln-DTPA-
trastuzumab, prior to and after 12 weekly trastuzumab doses and concomitant 3-
weekly paclitaxel. Cardiac assessments were performed before treatment, after 4 and
6 cycles. Plasma N-terminal proB-type natriuretic peptide (NT-proBNP) and serum
troponin |  (Tnl )  were measured wi th immunoassay.
Fifteen of the 17 patients were available for cardiac and tumor uptake analysis. Pre-
treatment myocardial l l t ln-DTPA-trastuzumab uptake was observed in one patient
with pre-existent cardiac arrhythmias, who did not develop heart failure during
treatment. Severe cardiotoxicity occurred in three patients, without init ial myocardial
1111n-DTPA-trastuzumab uptake, while one showed weak myocardial uptake after 4
't63
CHAPTER 9.
cycles. The detection rate of single tumor lesions was 45%. New tumor lesions were
discovered in 13 115 patients. Pre-treatment plasma NT-proBNP levels were higher in
patients with, than without heart failure (mean 534 t SD 236 vs. 105 + 79 nglL'
p=0.009).
In  conclus ion,  radio labeled t rastuzumab sc int igraphy was not  va luable in  predict ing
trastuzumab-related cardiotoxicity in metastatic breast cancer patients, but can
identify HER2-positive tumors. Measurement of plasma NT-proBNP is promising
regarding prediction of trastuzumab-related cardiotoxicity.
